<p>在今天发布的一份报告中，巴克莱的 Eliana Merle 维持了对 Madrigal Pharmaceuticals 的买入评级，目标价为 964.00 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>根据 TipRanks，Merle 是一位 3 星分析师，平均回报率为 3.8%，成功率为 41.22%。Merle 覆盖医疗保健行业，专注于 Alnylam Pharma、BridgeBio Pharma 和 BioMarin Pharmaceutical 等股票。</p>
<p>除了巴克莱，Madrigal Pharmaceuticals 还在昨天的报告中获得了 H.C. Wainwright 的 Andrew Fein 的买入评级。然而，在同一天，美国银行证券重申了对 Madrigal Pharmaceuticals（NASDAQ: MDGL）的持有评级。</p>

Madrigal制药

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做多 - Direxion

医疗业 ETF - SPDR

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

<p>巴克莱分析师 Eliana Merle 对 Madrigal Pharmaceuticals (MDGL) 维持了买入评级，目标价为 964.00 美元。Merle 是一位 3 星分析师，平均回报率为 3.8%，成功率为 41.22%。此外，H.C. Wainwright 的 Andrew Fein 也对该公司发布了买入评级，而美国银行证券在同一天重申了持有评级</p>

<p>In a report released today, Eliana Merle from Barclays maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $964.00.</p>
<div class="lb-trans"><p>在今天发布的一份报告中，巴克莱的 Eliana Merle 维持了对 Madrigal Pharmaceuticals 的买入评级，目标价为 964.00 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>According to TipRanks, Merle is a 3-star analyst with an average return of 3.8% and a 41.22% success rate. Merle covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, BridgeBio Pharma, and BioMarin Pharmaceutical.</p>
<div class="lb-trans"><p>根据 TipRanks，Merle 是一位 3 星分析师，平均回报率为 3.8%，成功率为 41.22%。Merle 覆盖医疗保健行业，专注于 Alnylam Pharma、BridgeBio Pharma 和 BioMarin Pharmaceutical 等股票。</p>
</div><p>In addition to Barclays, Madrigal Pharmaceuticals also received a Buy from H.C. Wainwright’s Andrew Fein in a report issued yesterday. However, on the same day, Bank of America Securities reiterated a Hold rating on Madrigal Pharmaceuticals (NASDAQ: MDGL).</p>
<div class="lb-trans"><p>除了巴克莱，Madrigal Pharmaceuticals 还在昨天的报告中获得了 H.C. Wainwright 的 Andrew Fein 的买入评级。然而，在同一天，美国银行证券重申了对 Madrigal Pharmaceuticals（NASDAQ: MDGL）的持有评级。</p>
</div>

Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays

Tip Ranks

巴克莱银行

阿里拉姆制药

Bridgebio Pharma

拜玛林制药

美国银行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Madrigal 制药（MDGL）获得巴克莱银行的买入评级